(Q33376638)

English

Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure (English)

1 reference

Europe PubMed Central

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

10

object named as

Hagop Kantarjian

1 reference

Europe PubMed Central

26 July 2017

6

object named as

Stefan Faderl

1 reference

Europe PubMed Central

26 July 2017

Jorge Eduardo Cortes

1

object named as

Jorge Cortes

1 reference

Europe PubMed Central

26 July 2017

4

object named as

Susan O'Brien

1 reference

Europe PubMed Central

26 July 2017

8

object named as

Francis Giles

1 reference

Europe PubMed Central

26 July 2017

Guillermo Garcia-Manero

3

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

26 July 2017

7

object named as

Theresa Ebarb

1 reference

Europe PubMed Central

26 July 2017

author name string

Alfonso Quintás-Cardama

2

1 reference

Europe PubMed Central

26 July 2017

Dan Jones

5

1 reference

Europe PubMed Central

26 July 2017

Deborah Thomas

9

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

1 November 2007

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

110

1 reference

Europe PubMed Central

26 July 2017

9

1 reference

Europe PubMed Central

26 July 2017

2000-2006

1 reference

Europe PubMed Central

26 July 2017

BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23006

21 January 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23006

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimal residual disease in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23006

7 January 2021

based on heuristic

inferred from DOI database lookup

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23006

7 January 2021

based on heuristic

inferred from DOI database lookup

Punish the parent not the progeny.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23006

7 January 2021

based on heuristic

inferred from DOI database lookup

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23006

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23006

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23006

7 January 2021

based on heuristic

inferred from DOI database lookup

Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23006

7 January 2021

based on heuristic

inferred from DOI database lookup

RAS and leukemia: from basic mechanisms to gene-directed therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23006

7 January 2021

based on heuristic

inferred from DOI database lookup

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23006

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23006

7 January 2021

based on heuristic

inferred from DOI database lookup

Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23006

7 January 2021

based on heuristic

inferred from DOI database lookup

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23006

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23006

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23006

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23006

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23006

7 January 2021

based on heuristic

inferred from DOI database lookup

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23006

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23006

7 January 2021

based on heuristic

inferred from DOI database lookup

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23006

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23006

7 January 2021

based on heuristic

inferred from DOI database lookup

Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23006

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.23006

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33376638&oldid=1858462884"